Navigation Links
Synbiotics Corporation Announces Human Submission for FluDetect(R)
Date:3/13/2008

KANSAS CITY, Mo., March 13 /PRNewswire/ -- Synbiotics Corporation today announced that it is seeking 510(k) authorization from the Food & Drug Administration (FDA) for the use of its FluDetect(R) Avian Influenza Virus rapid test strip in humans. This represents Synbiotics first foray into the human point-of-care diagnostic marketplace. While it is not Synbiotics' initial intent to market this product itself to the human field, it is actively seeking an established strategic human diagnostic partner, to market, sell and distribute this product.

Currently, the FluDetect(R) product is the only USDA approved rapid point of care test for avian influenza in the veterinary field. FluDetect(R) has been heralded for its extreme sensitivity in a simple to use test format that requires no equipment, nor extensive training to perform. Management believes this may be the first crossover test to be licensed for use both in humans and animals and can be a vital tool to healthcare institutions for both seasonal flu testing as well as in endemic situations.

"The feedback we have received on the outstanding field performance of FluDetect(R) in avian influenza has encouraged us to seek human use," said Paul Hays, Synbiotics' President & Chief Executive Officer. "It is our goal to find a partner in a timely fashion to be prepared to enter the human market for the 2008-2009 flu season," said Hays. Inquiries by potential partners should be made to Ronan Molloy at ronanm@synbiotics.com.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostic products for the poultry, livestock and companion animal markets worldwide. Synbiotics is an expert in avian influenza surveillance and early detection. Synbiotics manufactures and distributes its products through its operations in San Diego, California, and Lyon, France. For information on Synbiotics and its products, visit the Company's website at http://www.synbiotics.com.

Contacts: Paul Hays

Synbiotics Corporation

1-816-464-3502


'/>"/>
SOURCE Synbiotics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
5. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
6. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
9. CEL-SCI Corporation Announces 2007 Financial Results
10. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):